Lyra Therapeutics

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ENLIGHTEN II is the second of two Phase 3 trials enrolling surgically-naïve CRS patients in the Global ENLIGHTEN clinical program. WATERTOWN, Mass.

Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients

WATERTOWN, Mass. , Sept. 6, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced the Company's participation at the H.C.

Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022

WATERTOWN, Mass. , Aug. 29, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that the company will present additional Phase 2 results from the LANTERN study for LYR‑210, the company's lead product candidate for chronic rhinosinusitis, at the 68th Annual Meeting of the American Rhinologic Society (ARS), taking place September 9-10, 2022 in Philadelphia.

Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting

Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of -26.47% and 92.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Lags Revenue Estimates

Pivotal ENLIGHTEN Phase 3 clinical program and BEACON Phase 2 clinical trial targeting a broad spectrum of chronic rhinosinusitis  (CRS) patients, continued enrollment Industry leader Richard Nieman, MD, appointed Chief Medical Officer In April 2022, secured $96.3 million in net proceeds in an at-the-market, private placement of common stock that is expected to support two pivotal data readouts; cash runway extended until mid-2024 WATERTOWN, Mass. , Aug. 9, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA)("Lyra" or the "Company"), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today reported financial results for the second quarter ended June 30, 2022, and highlighted recent accomplishments.

Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Here is how Lyra Therapeutics, Inc. (LYRA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.

Has Lyra Therapeutics (LYRA) Outpaced Other Medical Stocks This Year?

WATERTOWN, Mass. , July 5, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced participation at the William Blair Biotech Focus Conference 2022 (the Conference).

Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022

Industry leader with substantial U.S. and global experience in drug development and medical affairs joins Lyra as the Company's late-stage product candidates advance in the clinic WATERTOWN, Mass. , July 5, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Richard Nieman, MD, has been appointed Chief Medical Officer, effective July 11, 2022.

Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer

WATERTOWN, Mass. , May 26, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D.

Lyra Therapeutics to Present at Upcoming Investor Conferences

Phase 3 trials for LYR-210 are underway. LYR-210 has shown an excellent efficacy and safety profile.

Lyra Therapeutics: Progress In The Clinic

In April 2022, secured $100.5 million in gross proceeds in an at-the-market, private placement of common stock that is expected to support two pivotal data readouts; cash runway extended until mid-2024 Pivotal ENLIGHTEN Phase 3 clinical program and BEACON Phase 2 clinical trial targeting a broad spectrum of CRS patients actively recruiting patients WATERTOWN, Mass. , May 10, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today reported financial results for the first quarter ended March 31, 2022, and highlighted recent accomplishments.

Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

LYR-210 provided up to 24 weeks of clinically meaningful global symptom improvement in CRS patients LYR-210 achieved significant improvement in each CRS symptom subdomain of the SNOT-22 compared to control LYR-210 may improve mental and physical health and quality of life of CRS patients WATERTOWN, Mass. , April 29, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today is presenting additional, new data from its LANTERN Phase 2 study of LYR-210 in adult patients with chronic rhinosinusitis (CRS) at the 2022 Combined Otolaryngology Spring Meetings (COSM) being held April 27 – May 1, 2022 in Dallas, Texas.

Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022

Affirm

CCC Intelligent Solutions Holdings

Alphabet

Liquidia Technologies Inc

Rocket Companies, Inc.

CBRE Global Real Estate Income Fund

These seven stocks show varying degrees of insider trading, which can provide a hint regarding each company or fund's performance. The post 7 Stocks to Watch for Major Insider Trading Clues appeared first on InvestorPlace.

7 Stocks to Watch for Major Insider Trading Clues

WATERTOWN, Mass. , April 25, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (NASDAQ: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose, and throat (ENT) passages and other diseased tissues, today announced that the first patient was treated in the Part 1/non-randomized portion of the Phase 2 BEACON clinical trial of LYR-220 in adult patients with chronic rhinosinusitis (CRS) who have had a prior sinus surgery.

Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

LYR-210 Data on Impact of Long-Acting Implantable Corticosteroid Matrices in Patients with CRS Selected as a Top Clinical Abstract Both Presentations Demonstrate Potential Benefit of LYR-210 to Chronic Rhinosinusitis Patients WATERTOWN, Mass. , April 21, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that two new abstracts highlighting additional LANTERN study data evaluating LYR-210 in chronic rhinosinusitis (CRS) have been selected for podium presentations at the upcoming 2022 Combined Otolaryngology Spring Meetings (COSM) being held April 27 – May 1, 2022 in Dallas, Texas.

Lyra Therapeutics Announces Two Presentations at Upcoming COSM 2022

Private placement priced at-the-market under Nasdaq rules Proceeds to support Lyra's ongoing clinical development of LYR-210 and LYR-220 Proceeds, combined with existing cash and expected milestone payments, supports extension of cash runway into mid-2024 WATERTOWN, Mass. , April 13, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages, today announced the closing of its previously announced private placement of common stock (or, in lieu thereof, pre-funded warrants to purchase common stock), resulting in gross proceeds of approximately $100.5 million.

Lyra Therapeutics Announces Closing of $100.5 Million Private Placement

Aterian

Biofrontera

Medavail Holdings Inc

ENDRA Life Sciences

We're diving into the top penny stocks for today in our market update for Friday with all the latest news that's moving shares! The post Top Penny Stocks Today: Why ATER, BFRI, NDRA, MDVL and LYRA Stocks Are Soaring Friday appeared first on InvestorPlace.

Top Penny Stocks Today: Why ATER, BFRI, NDRA, MDVL and LYRA Stocks Are Soaring Friday

Lyra Therapeutics Inc (NASDAQ: LYRA) has announced a private placement of approximately $100.5 million. The Company has offered 18.8 million common shares at $4.22 per share and pre-funded warrants to purchase an aggregate of 5 million shares with an exercise price of $0.001 per share,.

Lyra Therapeutics Stock Surges On Equity Raise Of $100M

WATERTOWN, Mass., April 8, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) today announced that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $100.5 million, before deducting offering expenses.

Lyra Therapeutics Announces $100.5 Million Private Placement

WATERTOWN, Mass., March 9, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today reported financial results for the quarter ended December 31, 2021, and highlighted recent accomplishments and upcoming milestones.

Lyra Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

WATERTOWN, Mass., March 7, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced the appointment of Jim Tobin to its Board of Directors (BOD).

Lyra Therapeutics Appoints Jim Tobin to Board of Directors

WATERTOWN, Mass., Feb. 28, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced the enrollment of the first patient in the Phase 3 ENLIGHTEN I clinical trial of LYR-210 in adult patients with chronic rhinosinusitis (CRS).

Lyra Therapeutics Announces First Patient Dosed in Pivotal ENLIGHTEN I Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients

WATERTOWN, Mass., Feb. 17, 2022 /PRNewswire/ -- Lyra Therapeutics today announced the appointment of Harlan W.

Lyra Therapeutics Appoints Harlan W. Waksal, MD, as Executive Chairman

Lyra Therapeutics Inc (NASDAQ: LYRA) has initiated its Phase 3 ENLIGHTEN I trial of LYR-210 in adult, surgically naïve chronic rhinosinusitis (CRS) patients. LYR-210 is designed to be administered in a brief, non-invasive, in-office procedure and deliver up to six months of continuous anti-inflammatory medication to the sinonasal passages.

Lyra Therapeutics Kickstarts LYR-210 Pivotal Program in Surgically Naïve Chronic Rhinosinusitis Patients

WATERTOWN, Mass., Jan. 24, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced the initiation of the Phase 3 ENLIGHTEN I clinical trial of LYR-210 in adult, surgically naïve chronic rhinosinusitis (CRS) patients, with trial sites open for enrollment.

News for Lyra Therapeutics Stock (LYRA)